National Institute of Radiological Sciences

National Institutes for Quantum and Radiological Science and Technology

Kyoto University

Taisho Pharmaceutical Co., Ltd.

Nihon Nohyaku Co., Ltd.

Public University Corporation Yokohama City University

Resvo Inc.

Ishikawa, Toru

Tetsuya Suhara

Makoto Higuchi

Meiei Cho

Masahiro Maruyama

Hitoshi Shimada

Haruhisa Inoue

Hiroki Takeuchi

Ryosuke Takahashi

Bin Ji

Atsuro Nakazato

Tomoyuki Miyazaki

Takuya Takahashi

Makoto Goto

Ming-Rong Zhang

Kazutoshi Suzuki

Arata Ohnishi

Takafumi Minamimoto

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof:

Compounds for imaging tau proteins that accumulate in the brain

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein:  represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.

Compounds for imaging tau proteins that accumulate in brain

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: 

The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO; each of X and Y independently represents S or O; each of R-Rindependently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each Rindependently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.

Compound that specifically binds to AMPA receptor

The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free &#x3ba; immunoglobulin chains and free &#x3bb; immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free &#x3ba; immunoglobulin chains, free &#x3bb; immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects. The biomarker enables more effective tests and diagnoses to be conducted combining inflammatory cytokines in the blood of patients with psychiatric and neurological disorders.

Biomarker for psychiatric and neurological disorders

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

Vaccine for treatment of tautopathy

This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.

A phenyloxyaniline derivative useful as a ligand for peripheral benzodiazepine receptor having a strong affinity and a high selectivity, which is represented by formula (1):wherein Xand Xare same or different and each is hydrogen atom or halogen atom; Rand Rare same or different and each is hydrogen atom, an alkyl group having 1 to 10 carbon(s) or a halogen-substituted alkyl group having 1 to 10 carbon(s); and Ris a halogen-substituted alkyl group having 1 to 5 carbon(s), or a radioisotope thereof.

Growing community of inventors

Chiba, Japan

Tetsuya Suhara